Table 2.
Baseline and clinical characteristics of all subjects by treatment
| Continuous variables | SP (n = 199) | AS/SP (n = 212) | Total (n = 411) | p-value |
| Haemoglobin (g/dL) (mean/SD) | 11.0 2.1) | 11.4 (2.1) | 11.2 (2.1) | 0.07* |
| Temperature (°C) (mean/SD) | 37.6 (1.2) | 37.4 (1.2) | 37.5 (1.2) | 0.251* |
| Dose of pyrimethamine (mg/kg) (mean/SD) | 1.7(0.7) | 1.8 (0.6) | 1.7 (0.6) | 0.645* |
| Dose of artesunate (mg/kg) (mean/SD) | N/a | 11.4 (3.0) | 11.4 (3.0) | N/a |
| Age (years) (median/IQR) | 10.0 (5.0–22.0) | 12.0 (5.0–24.0) | 11.0 (5.0–23.0) | 0.237# |
| Weight (kg) (median/IQR) | 25.0 (15.0–52.0) | 28.0 (15.0–55.0) | 25.8 (15.0–54.0) | 0.508# |
| Parasite density (per μl) (geometric mean/95% CI) | 3630.7 (2464.8; 5348.1) |
2885.2 (2028.4; 4104.0) |
3225.6 (2486.3; 4184.8) |
0.284# |
| Log parasite density (per μl) (median/IQR) | 3.8 (2.5–4.5) | 3.6 (2.5–4.5) | 3.7 (2.5–4.5) | 0.315# |
| Duration malaria symptoms (days) (median/IQR) | 1.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.347# |
| Categorical variables (n/%) | ||||
| Gender male | 76 (38) | 94 (44) | 170 (41) | 0.206^ |
| Age 7 years or under | 84 (42.2) | 79 (37.3) | 163 (39.7) | 0.306^ |
| Anaemic (haemoglobin < 11 g/dL)1 | 94 (47) | 94 (44) | 188 (46) | 0.556^ |
| Severely anaemia (haemoglobin < 7 g/dL)1 | 6 (3) | 2 (1) | 8 (2) | 0.129^ |
| History of vomiting | 20 (10) | 17 (8) | 37 (9) | 0.472^ |
| History of vomiting, with fever on day 0 | 9 (5) | 6 (3) | 15 (4) | 0.361^ |
| Vomited within 1 hour of any dose | 7 (4) | 12 (6) | 19 (5) | 0.301^ |
| Diarrhoea in first 24 hrs post dose | 14 (7) | 7 (3) | 21 (5) | 0.086^ |
| Diarrhoea between days 2 and 7 | 7 (4) | 5 (2) | 12 (3) | 0.485^ |
| Quintuple mutation | 45/195 (23.1) | 39/210 (18.6) | 84(20) | 0.289^ |
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamine
1 WHO 2001
N/a Not applicable
* Student's two sample t-tests
#Wilcoxon rank sum test
^Chi-square or Fisher's exact tests